News

Search:

Watson Files Suit Against FDA over 180-Day Exclusivity

0 Likes

Generics manufacturer Watson Pharmaceuticals has filed a lawsuit against the US Food and Drug Administration (FDA) in an attempt to compel the agency to grant it 180-day generic marketing exclusivity Read More...

Tags:

Actos

ANDA

Diabetes

Exclusivity

FDA

Watson

FDA Approves Generic Lexapro

0 Likes

The US Food and Drug Administration (FDA) today approved Israeli pharmaceutical manufacturer Teva Pharmaceutical Industries to legally market generic Lexapro for depression and generalized anxiety Read More...

Tags:

180-Day

ANDA

Antidepressant

Exclusivity

FDA

Forest

Generic

Lexapro

Teva

Administration Budget Forcefully Against 'Pay-For-Delay,' Industry

1 Likes

The Fiscal 2013 federal budget released on 13 February by the Obama administration laid out more than just the proposed spending levels for dozens of federal agencies, including the US Food and Drug Read More...

Tags:

Biologics

Budget

Exclusivity

FDA

FTC

FY2013

Leibowitz

Medicaid

Medicare

OMB

Pay For Delay

PhRMA

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Most Viewed
Most Popular

Most Viewed

FDA Plans Huge Cardiovascular Registry With Focus on Medical Devices 2 April 2013
In Unprecedented Shift, EU Parliament Proposes Premarket Authorization for Medical Devices 15 April 2013
Goodbye, KFDA: Korean Regulator Gets New Name, Decentralized Authority After Reorganization 28 March 2013
FDA Gets Go-Ahead for Study of DTC Advertising and Social Media 18 April 2013
UPDATED: President's Budget Proposal Calls for Small Increases at FDA, but Big Changes for Industry 11 April 2013
IBM Awarded Huge Contract to Modernize Regulatory Review Processes at FDA 29 April 2013
New FDA Document Clarifies IND Process for Drugs, Biologics and Biosimilars 30 April 2013
Warning Letter to Company Cites Low Supplies of Toilet Paper 15 May 2013

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Watson Files Suit Against FDA over 180-Day Exclusivity

FDA Approves Generic Lexapro

Administration Budget Forcefully Against 'Pay-For-Delay,' Industry

Get RF Today